Table 1.
Clinical characteristics of the study population
| Characteristics | Nicorandil group (n = 30) | Control group (n = 30) |
|---|---|---|
| Male (%) | 19 (63.33%) | 22 (73.33%) |
| Age (years) | 59.97 ± 1.32 | 60.43 ± 1.26 |
| STEMI (n, %) | 12 (40%) | 11 (36.67%) |
| NSTEMI (n, %) | 9 (30%) | 11 (36.67%) |
| UAP (n, %) | 9 (30%) | 8 (26.67%) |
| BMI (kg/m2) | 24.77 ± 0.67 | 25.22 ± 0.61 |
| Smoking (%) | 11 (36.67%) | 14 (46.67%) |
| Diabetes history | 12 (40%) | 10 (33.33%) |
| Hypertension | 19 (63.3%) | 21 (70%) |
| Systolic BP (mmHg) | 131.17 ± 3.90 | 130.03 ± 2.96 |
| Diastolic BP (mmHg) | 75.03 ± 2.48 | 79.63 ± 1.72 |
| Heart rate (bpm) | 70.00 ± 1.72 | 72.07 ± 2.66 |
Data are expressed as mean ± SEM or number (%) of participants. There were no significant differences in the clinical characteristics between the patients in the control group and the nicorandil group.
Abbreviations: BMI, body mass index; BP, blood pressure; NSTEMI, non‐ST segment elevation myocardial infarction; STEMI, acute ST segment elevation myocardial infarction; UAP, unstable angina pectoris.